Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjEd5JVOi53IN88US=> NYHNNZFOOS12IHS= MorpSG1UVw>? M{[4XYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv Mn3UNlU1QTB|OEO=
H1703 NUDhXXNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PQZ|IvPSEQvF2= MYixMVQh\A>? MmHTSG1UVw>? M4HKe4VvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv NWrERZh7OjV2OUCzPFM>
HUVECs NW\jRlBnS3m2b4TvfIlkcXS7IFHzd4F6 NXXZepl7OTByIH7N MVuyOEBp NIHJepRifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M3j2cFI2PDVyMUi2
APRE-19 MYjBdI9xfG:|aYOgRZN{[Xl? NYHXVYNtPSEQvF2= MmLFNlQhcA>? M2HIZYFjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 M2q0VlI2OzJ7NkG3
MDA-MB-231 MkXsRZBweHSxc3nzJGF{e2G7 NEPlcm0yyqEQvF5CpC=> MXO0PEBp MX7EUXNQ M4nxOIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg NGSyOXkzPTNyMEmzNi=>
MCF7 NELVOpNHfW6ldHnvckBCe3OjeR?= NWTY[2J2OTByIH7N MXKyOEBp MXrlcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> NUP1d2s2OjVzN{K1OVc>
HT-29  M{mz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDMNU42yqEEtV2= MYK5OkBp M2rFd4Rm[3KnYYPld{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgbY5pcWKrdHXkJIJ6KEu\TlG= NVnQPVZDOjVyMUKxNlM>
MO59K  MV3DfZRwfG:6aXPpeJkhSXO|YYm= M{nCcFXDqM7:TR?= NEH3e3k4KGR? MXPEUXNQ M17RbIVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= NFSxUWQzPDl3M{W2NS=>
MO59J MXrDfZRwfG:6aXPpeJkhSXO|YYm= M1PEZlXDqM7:TR?= MlfIO{Bl MlrYSG1UVw>? M3jTPYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MXeyOFk2OzV4MR?=
MO59K  MlToRZBweHSxc3nzJGF{e2G7 NW\0cYJZOTBizszN NUn6fGZIOjRiaB?= MkPPSG1UVw>? MoXXbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv M3nSR|I1QTV|NU[x
MO59J Ml7HRZBweHSxc3nzJGF{e2G7 NULLOpRZOTBizszN NG\MPIczPCCq M{i3TmROW09? MlrJbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MlHINlQ6PTN3NkG=
HepG2 NIrRRplHfW6ldHnvckBCe3OjeR?= MlnXNVAxKG6P MYGwMlUhcA>? MmLHSG1UVw>? MXjicI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u MXuyOFg3OzN3MB?=
A549  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKwcoxXOyEEtV5CpC=> MljsNkBp NGPNbmx{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w MYqyOFg1Pzh4Mx?=
A549  MYnGeY5kfGmxbjDBd5NigQ>? M3m5eVExyqEQvH5CpC=> M1zlNlE3KGh? M3LKZ2ROW09? M4HFfI1w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> NEGxXpkzPDhyMkGxNS=>
SK-N-LO MX7GeY5kfGmxbjDBd5NigQ>? Mn63NVAxKG6P NH7temYxNjViaB?= NUnmUpVy\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w NYXhdmZ6OjR4NUS2NFY>
HL-60 NVfzeWdYTnWwY4Tpc44hSXO|YYm= NHSwfZIxNjIEoN88US=> NF31V3A4OiCq MoOyZoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u NF;pSG4zPDZyN{K3Ny=>
HepG2  MlXiSpVv[3Srb36gRZN{[Xl? MWqyNFAhdk1? NXnj[pVOOC53IHi= MmTyZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? NXnTcFlGOjR3M{WxPVI>
H520 NX7CTndETnWwY4Tpc44hSXO|YYm= MlPvNVDDqM7:TR?= MnPKNUBp NGLyN|ZFVVOR MnKw[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NFi0fWEzPDR2N{mzOS=>
H1975 MWDGeY5kfGmxbjDBd5NigQ>? NI\ofpEyOMLizszN MVyxJIg> M2W2U2ROW09? MYrk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NUPjcndpOjR2NEe5N|U>
MG-63 NIfHUHpCeG:ydH;zbZMhSXO|YYm= MX[xNEDDvU1? NGLVPJAyOiCq MYHlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NXLCT3d4OjR|NUizNFE>
5637 MUXBdI9xfG:|aYOgRZN{[Xl? NY\5b3ExOTEEoN88US=> NYfxO|ZwPDBibXnu NVrZS|FjemW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw NEHS[lYzPDN|M{i2PC=>
HEK-293 NHXLSIJHfW6ldHnvckBCe3OjeR?= M3WxeFE2OG6P MUSxOkBp MXjEUXNQ NGfONoJl\WO{ZXHz[ZMhS1KWIHHjeIl3cXS7 NXjqdItIOjR|MkSzOlY>
SW480  NY[5NmxbTnWwY4Tpc44hSXO|YYm= M1P6TlE2OG6P M1TETVIxKGh? MoTVSG1UVw>? M{LrRZJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NW[4c5VMOjR|MkSzOlY>
HepG2 NGHlUFZHfW6ldHnvckBCe3OjeR?= MmHxNVAxKG6P M3TIV|I1KGh? M{LpVIF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz Mn;lNlQzQTd3MUC=
HCT 116  NWCwXWxOTnWwY4Tpc44hSXO|YYm= NHPNPVYyODBibl2= NVqzeoxSOjRiaB?= MWfheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MWWyOFI6PzVzMB?=
BEL/FU MYjGeY5kfGmxbjDBd5NigQ>? M363cVEhdU1? NXv3SWplOjRiaB?= MYrk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> NFL0XYwzPDJ|MkC5PS=>
Huh7  Ml\PSpVv[3Srb36gRZN{[Xl? NGi0dJE{yqEQvF2= MVmxJIg> MYHy[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> NYHHc|JiOjRzOESxPVY>
A-375 MUnBdI9xfG:|aYOgRZN{[Xl? MUi0M|gh|ryP NWPjdpZSOjRiaB?= MY\lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NXjKTVl[OjRzMUOxO|M>
A-375-TS  Mkm5RZBweHSxc3nzJGF{e2G7 M4LyO|QwQCEQvF2= MnPGNlQhcA>? NYLrWFdX\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MmnrNlQyOTNzN{O=
Mel-HO MUTBdI9xfG:|aYOgRZN{[Xl? M3;hUFQwQCEQvF2= Ml21NlQhcA>? NUPTWmJ2\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NXHGfWtxOjRzMUOxO|M>
Mel-HO-TS MYHBdI9xfG:|aYOgRZN{[Xl? MVK0M|gh|ryP MlH0NlQhcA>? MnPE[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= M{LOU|I1OTF|MUez
MeWo M4O0UGFxd3C2b4Ppd{BCe3OjeR?= NGjxV3A1NzhizszN MXqyOEBp NFftPG9mdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NUHtWFlGOjRzMUOxO|M>
Mel-2a NEDUdmlCeG:ydH;zbZMhSXO|YYm= MnnnOE85KM7:TR?= NVXTfo9nOjRiaB?= MYrlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MXmyOFEyOzF5Mx?=
MDA-MB-231 M4HPZmZ2dmO2aX;uJGF{e2G7 MXiw5qCUPDByIH7N M37aOFQhcA>? MVXzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFL4cJIzOjlyNkK1PS=>
MDA-MB-231 M4HTbWZ2dmO2aX;uJGF{e2G7 M{PGeFQxOCCwTR?= NIW5XFY1KGh? NEn0U4dl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M12xS|IzQTB4MkW5
Jurkat MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWNE4zPS1zLkK1JO69VQ>? NYPtW2RXOjRxNEigbC=> MoHTSG1UVw>? M4G3U4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NYLFToE4OTl5NUexPFU>
Namalwa NYT1[ok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PKZlAvOjVvMT6yOUDPxE1? MXyyOE81QCCq M2XwSWROW09? NHvwWWFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= M2DD[VE6PzV5MUi1
Jurkat MnPwRZBweHSxc3nzJGF{e2G7 MmfLNE4zPS1zLkK1JO69VQ>? NFPN[5MzPC92ODDo NXi0SJZHTE2VTx?= NHmxbZlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> Mn2zNVk4PTdzOEW=
Namalwa NE\vTmRCeG:ydH;zbZMhSXO|YYm= MWewMlI2NTFwMkWg{txO NF3VTmkzPC92ODDo M4TyOmROW09? MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= Mn;sNVk4PTdzOEW=
K562 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCbmxOOjRiaB?= MUXJR|UxRTJ3wsGwMlE1KG6P MYGxPVY3OjN4MR?=
SW1990 NIfwSVJHfW6ldHnvckBCe3OjeR?= M17mfFAvODFvMTFOwG0> M2Ky[FEhcA>? M2XCfYlvcGmkaYTzJGhCNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIPaXYkyQTR4OUCyNC=>
RT112  M1zVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7abmtOOTEEoN88US=> M17mXVI1KGh? NELzbldFVVOR NFy1NYll\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? M1TjO|E5Pzh5OEOy
MHG-U1 NIXCfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjQc4oyOMLizszN M1TYXVI1KGh? NUTCcHhITE2VTx?= NXf6RXZl\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? Ml7tNVg4QDd6M{K=
SMMC-7721 NVXNO3pMSXCxcITvd4l{KEG|c3H5 NWPwd4kyOjBywrDuUS=> MmDxNlQhcA>? NHXh[ZpqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| MVWxO|U2PzF7MR?=
SMMC-7721 MoXhSpVv[3Srb36gRZN{[Xl? NViyeoZuOjBywrDuUS=> NEP6R3czPCCq MmX3eZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? NXzLOI5QOTd3NUexPVE>
HeLa M3HpU2Z2dmO2aX;uJGF{e2G7 MWOxNFDDqG6PwrC= MoC4NUBp M13mOIFtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 NGfTSnAyPjh7MEmxOS=>
MRC5VI M2TYZmZ2dmO2aX;uJGF{e2G7 NWLS[mtvOTJwNTDtUS=> NVuxVZp[OC53IHi= MVfEUXNQ NFXOSJpi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MmnCNVYzOjd|OUS=
AT5BIVA MlPOSpVv[3Srb36gRZN{[Xl? MYSxNk42KG2P MXewMlUhcA>? M1rMcmROW09? MoTEZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NHu5U5AyPjJ{N{O5OC=>
M059J NYDaeII5TnWwY4Tpc44hSXO|YYm= NHPJVWQyOi53IH3N Ml\hNE42KGh? NFrPPWlFVVOR NHuzbVdi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NILBV3YyPjJ{N{O5OC=>
HeLa MXnGeY5kfGmxbjDBd5NigQ>? MnLRNVIvPSCvTR?= NXTI[4d2OC53IHi= M{LnU2ROW09? MofuZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MXGxOlIzPzN7NB?=
N2a NVPRUFZySXCxcITvd4l{KEG|c3H5 NX7OVo5COC5zLUGwJO69VQ>? NWjFOHVSOiCq NGDKRYFqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= M3[5UlE2QDR{N{[3
Jurkat  MVHLbY5ie2ViQYPzZZk> NGfw[3FKSzVyIH;mJFI1KG6P MlHsNVU3PjR3MUm=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID